The Access Consortium - consisting of the national regulatory authorities of Australia, Canada, Singapore, Switzerland and the United Kingdom - is pleased to present our updated strategic plan, which outlines our approach to regulatory collaboration for the coming years.
Our vision remains focused on enhancing cooperation amongst member countries to streamline procedures and improve access to safe, effective medicines. We aim to create an environment that benefits patients, industry partners, and regulatory bodies alike.
The renewed plan emphasises solidifying our collaborative processes, aligning expectations with industry, and improving our communication strategies. We're introducing a new cloud-based workspace to facilitate joint reviews, which we believe will enhance our efficiency.
Our key strategic objectives are:
- Strengthening work-sharing initiatives
- Expanding our lifecycle approach
- Supporting regulatory innovation
- Enhancing stakeholder engagement
We continue to encourage joint applications, particularly those involving all member countries, as these offer the greatest collaborative benefits.
The updated strategic plan is available on our newly launched Access Consortium webpage.
See our website to find out more about the Australia-Canada-Singapore-Switzerland-United Kingdom (Access) Consortium.
